SCHEDULE: T. Rowe Price Discloses 10% Stake in Samsara Inc.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.0% of Samsara Inc.'s common stock as of March 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has reported beneficial ownership of Samsara Inc. common stock.
• As of March 31, 2026, the firm beneficially owned 36,680,798 shares.
• This represents 10.0% of the class of securities.
• T. Rowe Price Associates, Inc. holds sole voting power over 35,344,507 shares and sole dispositive power over 36,680,798 shares.
• The filing is made under Rule 13d-1(b) and certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as it indicates a significant investment by a reputable institutional investor, suggesting confidence in Samsara Inc.'s long-term value.

Positives

• T. Rowe Price Associates, Inc., a significant institutional investor, has disclosed a substantial stake in Samsara Inc., indicating confidence in the company's prospects.
• The firm holds significant voting and dispositive power, suggesting a stable, long-term investment approach.

Negatives

• The filing does not contain any negative financial performance indicators or operational challenges for Samsara Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• The filing does not explicitly mention risks related to Samsara Inc.'s operations. However, as an institutional investor, T. Rowe Price Associates, Inc. would be subject to market risks, investment performance risks, and risks associated with the specific industry in which Samsara Inc. operates.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Samsara Inc. or T. Rowe Price Associates, Inc. regarding future performance.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake disclosures by major asset managers like T. Rowe Price often signal a positive view on a company's growth trajectory or market position within its sector, which for Samsara Inc. is the IoT and enterprise cloud software space.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major investor like T. Rowe Price may be viewed positively by other shareholders, potentially signaling increased institutional support and confidence in the company's future.
• Samsara Inc. Management: The increased scrutiny or potential influence from a large shareholder may require continued focus on delivering value and meeting investor expectations.
• Potential Investors: This filing may attract further attention from other investors interested in Samsara Inc., given the endorsement from a prominent asset manager.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold and manage its investment in Samsara Inc. according to its investment strategies.
• Samsara Inc. will continue its business operations and reporting as usual.

Key Dates

Keywords

Samsara Inc, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Disclosure